The clinical benefit rate was 59.4%, with one participant achieving a partial response and 18 showing stable disease.

Utah officials are spreading awareness of Valley fever, an infection that is caused by breathing in fungus spores that live ...

Nephrotoxicity was observed during the clinical trials of ARIKAYCE in patients with MAC lung disease but not at a higher frequency than background regimen alone. Nephrotoxicity has been ...

The MAC lung disease market is predicted to grow in the coming years. This growth is mainly driven by the launch of innovative therapies such as MNKD-101, Bedaquiline fumarate (TMC207), and SPR720 ...

MENLO PARK, Calif. - AN2 Therapeutics, Inc. (NASDAQ:ANTX), a small-cap biotech currently valued at $37.32 million, disclosed that its Phase 3 study of epetraborole for MAC lung disease did not meet ...

AN2 Therapeutics, Inc. (NASDAQ:ANTX), a small-cap biotech currently valued at $37.32 million, disclosed that its Phase 3 study of epetraborole for MAC lung disease did not meet the primary ...